drugset / Trial / NCT00483496
Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
RandomizedCrossoverSingle-blindSupportive care
Summary
Commercially available external photoprotectors (EP) do not provide adequate protection against ultraviolet A (UVA) and visible wavelengths. The proposed medicinal product V0096 CR (formula RV3131A-MV1166) is a broad spectrum EP (bsEP). The rationale for the use of V0096 CR (formula RV3131A-MV1166) in the proposed condition is based on its ability to broadly block the UVA radiations and visible light that are known to trigger solar urticaria (SU).
Timeline
- Start
- 2007-09
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ti02 pigmentary | Unknown | 3 % | Topical |
| Subject | Titanium dioxide (Ti02) microfine | Unknown | 12.15 % | Topical |
| Subject | bisoctrizole | Small molecule | 10 % | Topical |